These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 1110955)

  • 21. [Validity and limitations in the determination of serum properdin by means of zymosan].
    ZANUSSI C; TASCHINI P; SELVA G; ORTOLANI C
    Boll Ist Sieroter Milan; 1958; 37(5-6):237-45. PubMed ID: 13560652
    [No Abstract]   [Full Text] [Related]  

  • 22. Adaptation of the zymosan assay of properdin to animal sera.
    KENT JF; TOUSSAINT AJ; HOOK WA
    Proc Soc Exp Biol Med; 1957 Dec; 96(3):676-8. PubMed ID: 13505826
    [No Abstract]   [Full Text] [Related]  

  • 23. Alterations in serum properdin levels following injection of Zymosan.
    PILLEMER L; ROSS OA
    Science; 1955 May; 121(3151):732-3. PubMed ID: 14372981
    [No Abstract]   [Full Text] [Related]  

  • 24. Resistance to experimental peritonitis induced by local nonspecific stimulation of the reticuloendothelial system.
    Joyce LD; Mauer HG; Smith JM; Lillehei RC
    Adv Shock Res; 1980; 4():49-54. PubMed ID: 7315620
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Properties of highly purified human properdin.
    Ensky J; Hinz CF; Todd EW; Wedgwood RJ; Boyer JT; Lepow IH
    J Immunol; 1968 Jan; 100(1):142-58. PubMed ID: 4169693
    [No Abstract]   [Full Text] [Related]  

  • 26. [Shifts in the serum protein picture in patients with malignant neoplasms during chemotherapy of a complex nature with zymosan].
    Zakenfel'd GK
    Klin Lech Zlokach Novoobraz; 1968; 11():207-14. PubMed ID: 5725407
    [No Abstract]   [Full Text] [Related]  

  • 27. [Influencing of the serum properdin levels of patients with neoplasms by parenteral administration of zymosan].
    SZABO IK
    Orv Hetil; 1960 Feb; 101():222-5. PubMed ID: 13836258
    [No Abstract]   [Full Text] [Related]  

  • 28. Requirement for complement components and fibrinogen in the zymosan-induced release reaction of human blood platelets.
    Zucker MB; Grant RA; Alper CA; Goodkofsky I; Lepow IH
    J Immunol; 1974 Dec; 113(6):1744-51. PubMed ID: 4610046
    [No Abstract]   [Full Text] [Related]  

  • 29. [Effect of Zymosan on the properdin level of tumor patients].
    NAGY S; HARTAI F
    Acta Biol Med Ger; 1961; 6():99-102. PubMed ID: 13727492
    [No Abstract]   [Full Text] [Related]  

  • 30. Effect of injected zymosan on inhalation of particulates.
    Thomas RG; Scott JK; Thomas RL
    J Reticuloendothel Soc; 1969; 6(5):606-22. PubMed ID: 5349137
    [No Abstract]   [Full Text] [Related]  

  • 31. [The properdin titer in women with labor pathology or gynecological disease and the role of this titer in the prognosis].
    Malkov JJ
    Zentralbl Gynakol; 1975; 97(17):1047-56. PubMed ID: 1189778
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Kinetic studies of the formation of the properdin system enzymes on zymosan: evidence that nascent C3b controls the rate of assembly.
    Nicholson A; Brade V; Lee GD; Shin HS; Mayer MM
    J Immunol; 1974 Mar; 112(3):1115-23. PubMed ID: 4811964
    [No Abstract]   [Full Text] [Related]  

  • 33. [Behavior of the serum immunoglobulins in cases of malignant neoplasms].
    Fagiolo E; Sanso G
    Riv Anat Patol Oncol; 1967 Mar; 31(3):331-44. PubMed ID: 4178363
    [No Abstract]   [Full Text] [Related]  

  • 34. [Fibrinolysis and factors of aspecific immunity. Preliminary note].
    Ferrauto A; Giuffrida G; Terranova R
    Boll Soc Ital Biol Sper; 1965 Dec; 41(24):1488-91. PubMed ID: 5878160
    [No Abstract]   [Full Text] [Related]  

  • 35. Single pre-exposure to a high dose of zymosan enhances lung defense mechanisms and accelerates the pulmonary clearance of a bacterial pathogen in rats.
    Young SH; Antonini JM; Roberts JR
    Exp Lung Res; 2008 Nov; 34(9):559-78. PubMed ID: 19005921
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Radioprotective properties of zymosan].
    Chertkov KS; Khramchenkova SP; Rogozkin VD
    Radiobiologiia; 1973; 13(1):50-5. PubMed ID: 4719888
    [No Abstract]   [Full Text] [Related]  

  • 37. A nonlethal intravenous dose of endotoxin influences opsonized zymosan-stimulated [32P]phospholipid turnover in rat alveolar macrophages.
    Dowty BJ; Rodriguez de Turco E; Hagar A; Spitzer JA
    Circ Shock; 1992 Apr; 36(4):307-11. PubMed ID: 1623574
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quantity of hemolytic anti-A and anti-B in individuals of a human population: correlations with isoagglutinins and effects of the individual's age and sex.
    Grundbacher FJ
    Z Immunitatsforsch Allerg Klin Immunol; 1967 Dec; 134(4):317-49. PubMed ID: 4233546
    [No Abstract]   [Full Text] [Related]  

  • 39. [Data on the occurrence of alpha-1 and alpha-2 irregular isoagglutinins].
    Rex-Kiss B; Hartmann E
    Orv Hetil; 1970 May; 111(18):1046-7. PubMed ID: 5454004
    [No Abstract]   [Full Text] [Related]  

  • 40. [Treatment of late radiation ulcerations with a non-specific general stimulation. Appraisal of the method].
    Dobrek Z; Majewski S; Maciejewski B
    Przegl Dermatol; 1973; 60(5):665-70. PubMed ID: 4772497
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.